乳腺癌患者血浆中CCL18的表达水平及其意义

doi:10.3971/j.issn.1000-8578.2012.06.020

乳腺癌患者血浆中CCL18的表达水平及其意义

Expression Level and Significance of CCL18 in Plasma of Breast Cancer Patients

摘要

摘要: 目的探讨乳腺癌患者血浆中CCL18的表达水平及意义。方法收集广州医学院第一附属医院就诊乳腺肿瘤患者108例，均为女性。病理确诊的良性乳腺病20例，乳腺癌88例，乳腺癌组43例接受了新辅助化疗，均收集新辅助化疗前、后的血液标本，其余入组病例均收集初始干预前血液标本，另取36例健康女性体检者血液标本做为健康对照组。以酶联免疫吸附（ELISA）方法检测血浆中CCL18表达水平。结果乳腺癌组比健康对照组血浆中CCL18的表达水平明显升高，（P<0.05），乳腺癌组比良性乳腺病组血浆中CCL18表达水平明显升高（P<0.05）。血浆中CCL18表达水平与乳腺癌的雌激素受体（ER）存在负相关关系（P=0.018）。新辅助化疗效果达到临床缓解的患者化疗前后血浆中CCL18表达水平无明显变化（P=0.431），新辅助化疗效果未达到临床缓解的乳癌患者在化疗前后血浆中CCL18表达水平无明显变化（P=0.336）。结论 CCL18是乳腺癌的生物学标志物，其表达水平与乳腺癌的雌激素受体的表达相关，但尚不能作为乳腺癌化疗敏感度独立的预测指标。

Abstract: Objective To investigate the expression level and significance of CCL18 in the plasma of breast cancer patients. Methods 20 cases with benign breast diseases and 88 cases with breast cancer were studied.In the 88 breast cancer patients 43 cases received neoadjuvant chemotherapy.The 43 cases of breast cancer patients' blood specimens were collected before and after neoadjuvant chemotherapy,while the others samples were collected before any treatments.36 healthy women were collected as controls.The level of CCL18 in plasms was detected by enzyme linked immunosorbent assay(ELISA). Results The level of CCL18 in the breast cancer patients′ plasma was significantly higher than that in healthy group (P<0.01),and benign disease group (P<0.01).The correlation between the level of CCL18 in the plasma and erestrogen receptor (ER) was negative（P＝0.018）.There was no correlation between the CCL18 level and the neoadjuvant chemotherapy (P=0.431). Conclusion CCL18 is a biomarker of breast cancer,and negative correlation to the expression of estrogen receptor (ER).CCL18 is not an independent predictor for neoadjuvant chemotherapy in breast cancer.

HTML全文

参考文献(21)

施引文献

资源附件(0)